Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DAWN

Day One Biopharmaceuticals Inc

Feb 11 • 04:00PM ET

11.23

-0.19 -1.66 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX NBIX BPMC SRPT EXEL FATE IGMS KURA BHVN PBYI

| Held by: XBI VTI IWM VB VXF IWN IBB VBR SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.49	Insider Own	28.27%	Shs Outstand	102.68M	Perf Week	4.56%
Market Cap	1.19B	Forward P/E	-	EPS next Y	-0.55	Insider Trans	-0.19%	Shs Float	75.82M	Perf Month	-0.88%
Enterprise Value	738.38M	PEG	-	EPS next Q	-0.16	Inst Own	73.35%	Short Float	13.49%	Perf Quarter	10.53%
Income	-151.76M	P/S	8.88	EPS this Y	4.03%	Inst Trans	1.23%	Short Ratio	3.75	Perf Half Y	82.90%
Sales	133.67M	P/B	2.56	EPS next Y	44.25%	ROA	-27.23%	Short Interest	10.22M	Perf YTD	20.49%
Book/sh	4.39	P/C	2.63	EPS next 5Y	-	ROE	-30.16%	52W High	13.20 -14.92%	Perf Year	-5.79%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	28.09% -38.09%	ROIC	-33.46%	52W Low	5.64 99.29%	Perf 3Y	-43.57%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.44%	Volatility	6.71% 8.31%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.52	EPS Y/Y TTM	-46.75%	Oper. Margin	-123.90%	ATR (14)	0.83	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.55	Sales Y/Y TTM	31.11%	Profit Margin	-113.53%	RSI (14)	53.19	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	8.68	EPS Q/Q	-149.93%	SMA20	-1.48%	Beta	-1.27	Target Price	22.67
Payout	-	Debt/Eq	0.01	Sales Q/Q	-57.56%	SMA50	12.68%	Rel Volume	0.44	Prev Close	11.42
Employees	181	LT Debt/Eq	0.01	Earnings	Feb 24 AMC	SMA200	42.67%	Avg Volume	2.73M	Price	11.23
IPO	May 27, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.01% 5.21%	Trades		Volume	1,208,613	Change	-1.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-26	Resumed	TD Cowen	Buy	$34
Aug-19-25	Initiated	Piper Sandler	Overweight	$25
Oct-09-24	Reiterated	Needham	Buy	$32 → $33
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy	$11 → $24
Apr-24-24	Reiterated	Needham	Buy	$30 → $33
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform	$34 → $9
Feb-08-23	Initiated	CapitalOne	Overweight	$40
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy	$35
Dec-14-22	Initiated	Needham	Buy	$40
Dec-05-22	Initiated	Goldman	Buy	$45
Dec-01-22	Initiated	BofA Securities	Buy	$34

Show Previous Ratings

Feb-10-26 08:30AM	Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026 (GlobeNewswire)
Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool)
Feb-02-26 12:27PM	Will Declining Medical Customers Affect Cigna's Q4 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? (Zacks)
Jan-27-26 10:00AM	Best Momentum Stocks to Buy for January 27th (Zacks)
04:16AM	Loading…
04:16AM	New Strong Buy Stocks for January 27th (Zacks)
Jan-23-26 07:32AM	Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Jan-21-26 04:54AM	'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks (Benzinga)
Jan-15-26 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet (Zacks)
Jan-13-26 09:21AM	Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains? (Zacks) -6.53%
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily) +26.73%
10:56AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
Jan-11-26 05:00PM	Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance (GlobeNewswire)
Jan-08-26 05:00AM	Day One concludes Mersana Therapeutics acquisition (Pharmaceutical Technology)
Jan-06-26 09:02AM	Day One Completes Acquisition of Mersana Therapeutics (GlobeNewswire)
08:30AM	Loading…
Dec-16-25 08:30AM	Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 11:11PM	Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib) (Insider Monkey)
Dec-11-25 10:31AM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
Nov-24-25 08:00AM	Day One Announces Three Year Follow-Up Data From OJEMDA (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-18-25 08:30AM	Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-17-25 09:55AM	Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade (Zacks)
Nov-13-25 04:31PM	Mersana Therapeutics Catapults 200% On Day One Bio's Surprise Buyout (Investor's Business Daily) -14.41%
09:07AM	Mersana Catapults 200% On Day One Bio's Surprise Buyout (Investor's Business Daily)
06:59AM	Day One snaps up ADC maker Mersana in backloaded buyout deal (BioPharma Dive)
06:00AM	Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases (GlobeNewswire)
Nov-10-25 07:00AM	Day One Announces New OJEMDA (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-05-25 12:06AM	Day One Biopharmaceuticals Inc (DAWN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +25.21%
Nov-04-25 05:10PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Day One Reports Third Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
Nov-03-25 07:53AM	Day One Biopharmaceuticals Inc (DAWN) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
09:55AM	Loading…
Oct-30-25 09:55AM	Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? (Zacks)
Oct-21-25 08:30AM	Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 (GlobeNewswire)
Oct-14-25 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 241.59%: Read This Before Placing a Bet (Zacks)
Oct-06-25 09:40AM	Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last? (Zacks) -8.18%
Sep-16-25 08:01AM	Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock? (Zacks)
Sep-08-25 12:30AM	Piper Sandler Starts Coverage on Day One (DAWN) with Overweight Rating (Insider Monkey)
Aug-19-25 12:10AM	H.C. Wainwright Reiterates 'Buy' Rating on Day One Biopharmaceuticals, Inc. (DAWN) (Insider Monkey)
Aug-13-25 07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Aug-06-25 03:31AM	Day One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) -15.70%
Aug-05-25 04:00PM	Day One Reports Second Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
Aug-04-25 09:54AM	Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q2 2025 Result (GuruFocus.com)
Jul-24-25 09:55AM	Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade (Zacks)
Jul-22-25 08:30AM	Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 (GlobeNewswire)
Jun-10-25 08:30AM	Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development (GlobeNewswire)
May-13-25 10:47AM	Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey)
May-09-25 07:54AM	Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-07-25 11:09AM	Q1 2025 Day One Biopharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.87%
03:21AM	Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
May-06-25 05:25PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.55%
04:01PM	Day One Reports First Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
May-05-25 10:00AM	Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com) -5.67%
May-03-25 02:13AM	Q1 2025 American International Group Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-23-25 02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-22-25 08:30AM	Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 (GlobeNewswire)
Apr-10-25 11:51PM	Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity (Seeking Alpha) -7.02% +5.33%
Apr-09-25 09:44AM	Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple (Insider Monkey) +8.35%
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Mar-20-25 01:00AM	EXCLUSIVE: Plant Medicine Brand Apothékary Is Taking Customers on a $10,000 Immersive Trip to Japan (WWD)
Mar-05-25 09:00AM	Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory (Insider Monkey) +12.79%
Feb-25-25 05:55PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -16.50%
04:05PM	Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress (GlobeNewswire)
01:36AM	Day One Biopharmaceuticals Inc (DAWN) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-13-25 09:55AM	Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect? (Zacks)
Feb-11-25 08:30AM	Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 (GlobeNewswire)
Jan-28-25 08:56AM	Trump pledged to bring down food prices on Day One. Instead, eggs are getting more expensive (CNN Business)
05:30AM	Trump said hed bring prices down on Day One. That hasnt happened (CNN Business)
Jan-23-25 01:02AM	Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? (Insider Monkey)
Jan-22-25 08:44AM	New Tariffs Didnt Come on Trumps Day One. A Trade War May Not Be in the Wings. (Barrons.com)
Jan-20-25 03:31PM	President Trump outlines a frenzy of Day One executive orders and actions: Heres a list of what to expect (FastCompany)
Jan-13-25 08:00AM	Day One Reports Preliminary 2024 OJEMDA Net Product Revenue and Highlights 2025 Corporate Priorities (GlobeNewswire)
Dec-24-24 04:30PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-22-24 03:30PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-19-24 03:19PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-17-24 08:30AM	Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 09:49AM	How Trump Can Help Crypto on Day One (CoinDesk)
Dec-06-24 08:53PM	Instagram locks out developers of third-party consumer apps (TechCrunch)
Nov-27-24 10:18AM	Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts? (Insider Monkey)
Nov-20-24 04:30PM	Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development (GlobeNewswire)
Nov-18-24 08:30AM	Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-06-24 09:55AM	Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? (Zacks)
Oct-30-24 05:20PM	Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Day One Reports Third Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
Oct-21-24 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet (Zacks)
Oct-16-24 08:44AM	Day One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric Glioma (Insider Monkey)
08:30AM	Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 (GlobeNewswire)
Oct-01-24 08:00PM	At What Oil Price Will Shale Drillers Stop Drilling? (Oilprice.com)
Aug-27-24 12:49PM	Taylor Fritzs Girlfriend Morgan Riddle Opts for Classic Little Black Dress on Day One of the U.S. Open 2024 (WWD)
Aug-19-24 11:15AM	Jeff Bezos Said 'I Predict One Day Amazon Will Fail' And Claims Large Companies Only Last '30-Plus Years' Guess How Old Amazon Is? (Benzinga)
Aug-14-24 11:46AM	Bank of America Says Buy These 3 Stocks for a Double-Digit Rally (InvestorPlace)
Jul-30-24 01:52PM	DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
08:40AM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Day One Reports Second Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
07:00AM	Day One Announces Oversubscribed $175.0 Million Private Placement (GlobeNewswire)
Jul-25-24 11:53AM	Ipsen outlines $461m for ex-US rights to Day Ones glioma therapy (Pharmaceutical Technology)
12:58AM	Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor (GlobeNewswire)
Jun-27-24 09:51AM	Lupita Nyongo Shimmers in Sequined Off-the-shoulder Prada Jumpsuit and Satin Miniskirt at A Quiet Place: Day One Premiere (WWD)
Jun-24-24 04:50PM	Lupita Nyongo Gives Power Suiting a Sensual Spin in Double-breasted Blazer and High-waisted Shorts for A Quiet Place: Day One Photo Call (WWD)
Jun-22-24 04:11AM	Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN) (GuruFocus.com)
Jun-19-24 12:14PM	Day One targets the growing ADC market with MabCare acquisition (Pharmaceutical Technology)
10:29AM	Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up (Zacks)

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dubow Adam	Gen Counsel & Secretary	Nov 17 '25	Sale	8.91	4,319	38,503	62,626	Nov 18 07:04 PM
York Charles N II	COO and CFO	Nov 17 '25	Sale	8.91	4,062	36,212	294,715	Nov 18 07:02 PM
Merendino Lauren	Chief Commercial Officer	Nov 17 '25	Sale	8.91	3,726	33,216	50,809	Nov 18 07:00 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Nov 17 '25	Sale	8.91	15,894	141,690	177,165	Nov 18 06:59 PM
CHARLES YORK	Officer	Nov 17 '25	Proposed Sale	8.91	4,062	36,211		Nov 17 04:12 PM
LAUREN MERENDINO	Officer	Nov 17 '25	Proposed Sale	8.91	3,726	33,216		Nov 17 04:12 PM
ADAM DUBOW	Officer	Nov 17 '25	Proposed Sale	8.91	4,319	38,502		Nov 17 04:11 PM
JEREMY BENDER	Officer	Nov 17 '25	Proposed Sale	8.91	15,894	141,689		Nov 17 04:09 PM
York Charles N II	COO and CFO	Aug 18 '25	Sale	6.77	4,106	27,786	278,000	Aug 19 07:40 PM
Dubow Adam	Gen Counsel & Secretary	Aug 18 '25	Sale	6.77	4,365	29,538	54,858	Aug 19 07:38 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Aug 18 '25	Sale	6.77	16,058	108,666	161,365	Aug 19 07:37 PM
Merendino Lauren	Chief Commercial Officer	Aug 18 '25	Sale	6.77	3,766	25,485	41,931	Aug 19 07:36 PM
JEREMY BENDER	Officer	Aug 18 '25	Proposed Sale	6.77	16,058	108,666		Aug 18 05:33 PM
Merendino Lauren	Chief Commercial Officer	May 16 '25	Sale	6.26	3,927	24,575	35,161	May 19 05:54 PM
Dubow Adam	GENERAL COUNSEL	May 16 '25	Sale	6.26	4,552	28,486	47,136	May 19 05:48 PM
York Charles N II	COO, CFO AND SECRETARY	May 16 '25	Sale	6.26	4,282	26,796	265,231	May 19 05:45 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 16 '25	Sale	6.26	13,964	87,385	145,737	May 19 05:44 PM
CHARLES YORK	Officer	May 16 '25	Proposed Sale	6.26	4,282	26,796		May 16 04:09 PM
LAUREN MERENDINO	Officer	May 16 '25	Proposed Sale	6.26	3,927	24,575		May 16 04:09 PM
ADAM DUBOW	Officer	May 16 '25	Proposed Sale	6.26	4,552	28,486		May 16 04:08 PM
JEREMY BENDER	Officer	May 16 '25	Proposed Sale	6.26	13,964	87,385		May 16 04:08 PM
York Charles N II	COO, CFO AND SECRETARY	Feb 18 '25	Sale	11.96	4,370	52,278	252,638	Feb 21 06:10 PM
Dubow Adam	GENERAL COUNSEL	Feb 18 '25	Sale	11.96	4,646	55,580	39,602	Feb 21 06:08 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	11.96	12,048	144,130	128,015	Feb 21 06:05 PM
ADAM DUBOW	Officer	Feb 18 '25	Proposed Sale	11.96	4,646	55,580		Feb 18 06:07 PM
CHARLES YORK	Officer	Feb 18 '25	Proposed Sale	11.96	4,370	52,278		Feb 18 06:04 PM
JEREMY BENDER	Officer	Feb 18 '25	Proposed Sale	11.96	12,048	144,129		Feb 18 06:02 PM

Open in Screener

VIR

Vir Biotechnology Inc

Feb 11 • 04:00PM ET

7.42

-0.09 -1.20 %

Healthcare • Biotechnology • USA • NASD

VIR Vir Biotechnology Inc daily Stock Chart

Peers: REGN MRNA LLY PFE JNJ GILD BNTX AZN-D SNY NVAX

| Held by: IJR VTI XBI IWM VB VBK SPSM VXF IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-3.62	Insider Own	32.38%	Shs Outstand	139.02M	Perf Week	-1.07%
Market Cap	1.03B	Forward P/E	-	EPS next Y	-2.91	Insider Trans	-6.43%	Shs Float	94.07M	Perf Month	25.34%
Enterprise Value	623.75M	PEG	-	EPS next Q	-0.49	Inst Own	54.27%	Short Float	13.00%	Perf Quarter	38.18%
Income	-499.65M	P/S	61.23	EPS this Y	12.47%	Inst Trans	-3.23%	Short Ratio	6.75	Perf Half Y	70.38%
Sales	16.86M	P/B	1.30	EPS next Y	13.26%	ROA	-39.69%	Short Interest	12.23M	Perf YTD	23.05%
Book/sh	5.73	P/C	2.03	EPS next 5Y	14.29%	ROE	-49.06%	52W High	10.01 -25.87%	Perf Year	-18.19%
Cash/sh	3.66	P/FCF	-	EPS past 3/5Y	- -18.74%	ROIC	-56.31%	52W Low	4.16 78.58%	Perf 3Y	-71.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-59.24% 55.77%	Gross Margin	26.74%	Volatility	6.36% 7.40%	Perf 5Y	-89.69%
Dividend TTM	-	EV/Sales	37.00	EPS Y/Y TTM	7.74%	Oper. Margin	-3081.69%	ATR (14)	0.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.25	Sales Y/Y TTM	-78.55%	Profit Margin	-2963.54%	RSI (14)	56.54	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	7.25	EPS Q/Q	24.91%	SMA20	2.97%	Beta	1.69	Target Price	16.33
Payout	-	Debt/Eq	0.13	Sales Q/Q	-89.92%	SMA50	12.65%	Rel Volume	0.76	Prev Close	7.51
Employees	408	LT Debt/Eq	0.11	Earnings	Feb 23 AMC	SMA200	31.40%	Avg Volume	1.81M	Price	7.42
IPO	Oct 11, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-38.64% -87.90%	Trades		Volume	1,371,397	Change	-1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Initiated	Evercore ISI	Outperform	$12
Aug-27-25	Upgrade	BofA Securities	Neutral → Buy	$14
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62

Show Previous Ratings

Feb-09-26 04:05PM	Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire)
Jan-12-26 08:00AM	Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones (Business Wire)
Jan-05-26 04:05PM	Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-25 04:05PM	Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program (Business Wire) -5.25%
04:05PM	Loading…
Nov-19-25 04:05PM	Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-09-25 06:07PM	Vir Biotechnology Announces AASLD The Liver Meeting Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile (Business Wire)
Nov-07-25 09:00AM	Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference (Business Wire)
Nov-06-25 12:04AM	Vir Biotechnology Inc (VIR) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) -5.19%
Nov-05-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 08:00AM	Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta (Business Wire) -6.04%
Oct-29-25 11:48AM	GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View (Zacks) -8.09%
Oct-22-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) -5.56%
Oct-09-25 04:05PM	Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer (Business Wire)
09:27AM	Loading…
09:27AM	Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? (Zacks)
Oct-07-25 08:00AM	Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting 2025 (Business Wire)
Aug-27-25 04:21PM	Vir Stock Soars After BofA Boosts Rating on Liver Therapy (GuruFocus.com) +17.79%
09:34AM	Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly)
Aug-25-25 04:05PM	Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-06-25 06:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -14.37%
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results (Business Wire)
08:05AM	Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Jul-31-25 08:05AM	Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Jul-30-25 11:42AM	GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise (Zacks)
10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-25-25 05:50AM	First subject dosed in Phase I trial of Vir Biotechnologys VIR-5525 (Clinical Trials Arena)
Jul-24-25 08:05AM	Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors (Business Wire)
Jul-22-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 (Business Wire)
Jul-14-25 09:52AM	Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board (Business Wire)
09:40AM	Loading…
Jul-12-25 09:40AM	CoreWeave initiated, Texas Instruments upgraded: Wall Streets top analyst calls (TipRanks)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 09:31AM	Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? (Zacks)
May-28-25 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Business Wire) +9.03%
May-20-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit (Business Wire)
May-12-25 04:05PM	Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference (Business Wire) -11.32%
May-09-25 06:00AM	Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study (Business Wire) -6.01%
May-08-25 09:35AM	Q1 2025 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
03:31AM	Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-25 11:21PM	Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus (Seeking Alpha)
11:21PM	Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:15PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results (Business Wire)
Apr-30-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 (Business Wire)
11:45AM	GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance (Zacks)
Apr-24-25 09:30AM	Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 (Business Wire) +5.36%
Apr-09-25 09:43AM	Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple (Insider Monkey) +10.21%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 07:10AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results (PR Newswire)
Mar-13-25 08:05AM	Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -11.85%
02:24AM	Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Feb-26-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-19-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-12-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (Business Wire) +5.16%
Jan-23-25 06:35PM	Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now (Insider Monkey) +6.36% -5.09%
Jan-10-25 02:32PM	Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why (Benzinga)
Jan-09-25 08:30AM	Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 (Investing.com)
08:18AM	Vir Biotechnology Reports Promising Trial Results for Cancer Therapies (TipRanks)
Jan-08-25 04:06PM	Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment (Investor's Business Daily) +58.17%
07:45AM	Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC (Business Wire)
07:25AM	Vir Biotechnology price target lowered to $14 from $15 at BofA (TipRanks)
Dec-18-24 09:30AM	Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 04:05PM	Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta (Business Wire)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +12.88% -8.97%
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
Nov-26-24 09:30AM	Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Programs (Business Wire)
Nov-25-24 09:30AM	Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-18-24 09:15PM	Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program (Business Wire) -12.23%
04:05PM	Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency (Business Wire)
Nov-15-24 01:39PM	What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? (Benzinga) -7.29%
11:00AM	Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting (Business Wire)
Nov-01-24 05:01PM	Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +23.63%
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 05:20PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
Oct-18-24 03:04PM	State Street Corp's Strategic Acquisition in Vir Biotechnology Inc (GuruFocus.com)
Oct-17-24 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 (Business Wire)
Oct-15-24 08:16AM	Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 (Business Wire)
Oct-03-24 04:00PM	Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire) +5.59%
Sep-10-24 08:05AM	Vir Biotechnology Appoints Jason OByrne as Chief Financial Officer (Business Wire)
Sep-09-24 04:05PM	Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers (Business Wire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-22-24 08:05AM	Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-06-24 09:55AM	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? (Zacks)
Aug-01-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.34%
04:02PM	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities (Business Wire)
04:01PM	Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers (Business Wire)
Jul-18-24 04:05PM	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-26-24 08:05AM	Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection (Business Wire)
Jun-06-24 01:26PM	Vir Biotechnology (VIR) Up on Positive Data From HDV Study (Zacks) -5.37%
Jun-05-24 02:51PM	Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? (Benzinga) +19.66%
05:30AM	Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment (Business Wire)
May-29-24 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) -5.87%
08:05AM	Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer (Business Wire)
May-23-24 04:05PM	Vir Biotechnology to Host 2024 Annual Meeting of Stockholders (Business Wire) -6.33%
May-22-24 08:05AM	Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 (Business Wire) +11.36%

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SATO VICKI L	Director	Feb 02 '26	Sale	7.71	22,000	169,671	1,144,391	Feb 03 12:28 PM
SVF Endurance (Cayman) Limited	Stockholder	Jan 14 '26	Proposed Sale	6.82	1,251,303	8,533,886		Jan 14 09:00 PM
SATO VICKI L	Director	Jan 02 '26	Sale	5.93	22,000	130,383	1,166,391	Jan 05 01:57 PM
VICKI LEE SATO	Director	Jan 02 '26	Proposed Sale	6.03	66,000	397,980		Jan 02 04:29 PM
SVF Endurance (Cayman) Ltd	10% Owner	Dec 01 '25	Sale	5.98	191,854	1,147,786	13,728,924	Dec 03 04:30 PM
SATO VICKI L	Director	Dec 01 '25	Sale	6.00	22,000	132,070	1,188,391	Dec 02 07:48 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 26 '25	Sale	6.39	127,938	817,652	13,982,271	Dec 01 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 28 '25	Sale	6.44	61,493	396,015	13,920,778	Dec 01 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 25 '25	Sale	6.38	235,971	1,505,495	14,110,209	Nov 26 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 24 '25	Sale	6.15	227,803	1,400,783	14,346,180	Nov 26 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Nov 25 '25	Proposed Sale	6.44	1,251,303	8,058,391		Nov 25 09:00 PM
O'Byrne Jason	EVP & Chief Financial Officer	Nov 17 '25	Sale	5.56	6,799	37,782	110,701	Nov 18 02:47 PM
O'Byrne Jason	Officer	Nov 17 '25	Proposed Sale	5.56	6,799	37,781		Nov 17 03:20 PM
de Verneuil Vanina	EVP, General Counsel, Corp Sec	Nov 05 '25	Sale	5.16	2,385	12,307	78,210	Nov 07 03:27 PM
de Verneuil Vanina	Officer	Nov 05 '25	Proposed Sale	5.16	2,385	12,307		Nov 05 09:47 AM
de Verneuil Vanina	EVP and General Counsel	Nov 03 '25	Sale	5.86	1,365	8,003	80,595	Nov 04 07:40 PM
SATO VICKI L	Director	Nov 03 '25	Sale	5.64	22,000	124,047	1,210,391	Nov 04 11:58 AM
de Verneuil Vanina	Officer	Nov 03 '25	Proposed Sale	5.86	1,365	8,003		Nov 03 03:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 28 '25	Sale	6.50	24,453	159,006	14,574,083	Oct 30 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 29 '25	Sale	6.49	100	649	14,573,983	Oct 30 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 27 '25	Sale	6.05	66,403	401,585	14,598,536	Oct 28 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 24 '25	Sale	5.96	46,696	278,285	14,664,939	Oct 28 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 23 '25	Sale	5.99	154,383	924,723	14,711,635	Oct 24 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 22 '25	Sale	6.15	144,266	887,654	14,866,018	Oct 24 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 20 '25	Sale	6.20	220,535	1,367,273	15,119,959	Oct 22 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 21 '25	Sale	6.30	109,675	690,974	15,010,284	Oct 22 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Oct 21 '25	Proposed Sale	6.27	834,202	5,230,447		Oct 21 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 15 '25	Sale	6.07	16,671	101,196	15,353,338	Oct 17 04:15 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 16 '25	Sale	6.10	12,844	78,366	15,340,494	Oct 17 04:15 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 09 '25	Sale	6.14	249,060	1,529,926	15,372,309	Oct 14 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 10 '25	Sale	6.08	2,300	13,973	15,370,009	Oct 14 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 08 '25	Sale	6.05	466,242	2,819,785	15,621,369	Oct 09 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 07 '25	Sale	5.60	72,133	404,154	16,087,611	Oct 09 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 03 '25	Sale	5.56	450,342	2,501,785	16,233,699	Oct 07 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 06 '25	Sale	5.69	73,955	420,641	16,159,744	Oct 07 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Oct 03 '25	Proposed Sale	5.71	1,668,404	9,526,587		Oct 03 05:00 PM
SATO VICKI L	Director	Oct 01 '25	Sale	5.84	22,000	128,396	1,232,391	Oct 02 11:53 AM
VICKI LEE SATO	Director	Oct 01 '25	Proposed Sale	5.71	66,000	376,860		Oct 01 04:32 PM
SATO VICKI L	Director	Sep 02 '25	Sale	4.99	22,000	109,811	1,254,391	Sep 03 01:50 PM
SATO VICKI L	Director	Aug 01 '25	Sale	4.99	22,000	109,699	1,276,391	Aug 04 12:27 PM
Eisner Mark	EVP and Chief Medical Officer	Jul 15 '25	Sale	5.47	6,796	37,162	108,204	Jul 17 06:46 PM
Eisner Mark	EVP and Chief Medical Officer	Jul 17 '25	Sale	5.47	3,586	19,629	104,618	Jul 17 06:46 PM
MARK EISNER	Officer	Jul 17 '25	Proposed Sale	5.41	3,586	19,400		Jul 17 04:18 PM
Mark Eisner	Officer	Jul 15 '25	Proposed Sale	5.47	6,796	37,162		Jul 15 08:11 PM
SATO VICKI L	Director	Jul 01 '25	Sale	5.10	22,000	112,207	1,298,391	Jul 02 05:03 PM
VICKI LEE SATO	Director	Jul 01 '25	Proposed Sale	5.04	66,000	332,640		Jul 01 04:25 PM
GEORGE SCANGOS	Former Director	Jun 11 '25	Proposed Sale	5.41	19,957	108,037		Jun 11 05:59 PM
GEORGE SCANGOS	Former Director	Jun 10 '25	Proposed Sale	5.48	50,000	273,885		Jun 10 05:04 PM
GEORGE SCANGOS	Former Director	Jun 09 '25	Proposed Sale	5.41	50,000	270,590		Jun 09 05:55 PM
Napolitano Janet	Director	Jun 02 '25	Sale	5.05	3,200	16,149	16,416	Jun 02 07:26 PM
JANET ANN NAPOLITANO	Director	Jun 02 '25	Proposed Sale	4.94	3,200	15,808		Jun 02 04:29 PM
De Backer Marianne	Chief Executive Officer	Apr 03 '25	Sale	5.95	79,712	474,239	769,505	Apr 04 04:23 PM
Marianne De Backer	Officer and Director	Apr 03 '25	Proposed Sale	5.95	79,712	474,239		Apr 03 07:50 PM
de Verneuil Vanina	EVP and General Counsel	Feb 26 '25	Sale	9.14	7,373	67,402	79,460	Feb 27 12:39 PM
VANINA DE VERNEUIL	Officer	Feb 26 '25	Proposed Sale	9.10	7,373	67,094		Feb 26 04:23 PM
SCANGOS GEORGE A	Director	Feb 24 '25	Sale	9.45	10,056	95,063	698,239	Feb 25 03:44 PM
HANLY ANN M.	EVP & Chief Technology Officer	Feb 24 '25	Sale	9.45	14,168	133,936	117,901	Feb 25 03:43 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 24 '25	Sale	9.45	1,562	14,766	46,627	Feb 25 03:37 PM
De Backer Marianne	Chief Executive Officer	Feb 24 '25	Sale	9.45	16,122	152,408	849,217	Feb 25 03:36 PM
de Verneuil Vanina	EVP and General Counsel	Feb 24 '25	Sale	9.45	5,140	48,590	86,833	Feb 25 03:34 PM
George Scangos	Director	Feb 24 '25	Proposed Sale	9.45	10,056	95,063		Feb 24 08:57 PM
Brent Sabatini	Officer	Feb 24 '25	Proposed Sale	9.45	1,562	14,766		Feb 24 08:57 PM
Ann Hanly	Officer	Feb 24 '25	Proposed Sale	9.45	14,168	133,936		Feb 24 08:56 PM
Vanina de Verneuil	Officer	Feb 24 '25	Proposed Sale	9.45	5,140	48,590		Feb 24 08:40 PM
Marianne De Backer	Officer and Director	Feb 24 '25	Proposed Sale	9.45	16,122	152,408		Feb 24 08:38 PM
SCANGOS GEORGE A	Director	Feb 18 '25	Sale	9.81	10,964	107,575	708,295	Feb 19 07:11 PM
George Scangos	Director	Feb 18 '25	Proposed Sale	9.81	10,964	107,575		Feb 18 07:50 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 13 '25	Sale	9.15	1,562	14,291	28,189	Feb 14 06:41 PM
Brent Sabatini	Officer	Feb 13 '25	Proposed Sale	9.15	1,562	14,291		Feb 13 06:49 PM

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Feb 11 • 04:00PM ET

99.88

-1.03 -1.02 %

Healthcare • Biotechnology • USA • NASD

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-0.86	Insider Own	12.13%	Shs Outstand	51.31M	Perf Week	-3.92%
Market Cap	5.16B	Forward P/E	-	EPS next Y	-0.06	Insider Trans	-2.17%	Shs Float	45.41M	Perf Month	11.60%
Enterprise Value	5.11B	PEG	-	EPS next Q	0.04	Inst Own	99.11%	Short Float	17.17%	Perf Quarter	43.28%
Income	-41.42M	P/S	10.94	EPS this Y	86.38%	Inst Trans	6.77%	Short Ratio	10.27	Perf Half Y	54.33%
Sales	471.79M	P/B	17.55	EPS next Y	77.38%	ROA	-5.70%	Short Interest	7.80M	Perf YTD	26.45%
Book/sh	5.69	P/C	13.75	EPS next 5Y	-	ROE	-15.81%	52W High	105.74 -5.54%	Perf Year	99.12%
Cash/sh	7.27	P/FCF	116.48	EPS past 3/5Y	12.58% 4.14%	ROIC	-6.80%	52W Low	36.88 170.82%	Perf 3Y	321.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	160.13% -	Gross Margin	79.85%	Volatility	3.61% 3.89%	Perf 5Y	386.51%
Dividend TTM	-	EV/Sales	10.82	EPS Y/Y TTM	58.63%	Oper. Margin	-8.86%	ATR (14)	3.67	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.16	Sales Y/Y TTM	53.66%	Profit Margin	-8.78%	RSI (14)	61.92	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	3.31	EPS Q/Q	117.12%	SMA20	1.61%	Beta	0.51	Target Price	114.70
Payout	-	Debt/Eq	1.09	Sales Q/Q	47.17%	SMA50	18.54%	Rel Volume	0.69	Prev Close	100.91
Employees	322	LT Debt/Eq	1.08	Earnings	Nov 04 AMC	SMA200	49.98%	Avg Volume	759.22K	Price	99.88
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	135.66% 1.93%	Trades		Volume	520,900	Change	-1.02%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Feb-10-26 10:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-26 08:51AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire) -5.51%
08:00AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (Business Wire)
Feb-03-26 02:10AM	Mirum doubles down on diversified rare disease strategy (Pharma Voice)
Jan-31-26 03:22PM	Is Mirum Pharmaceuticals on a Strong Path to Profitability? (Motley Fool)
08:15AM	Loading…
08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-29-26 02:27PM	H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? (Insider Monkey)
Jan-27-26 06:33AM	Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline (Pharmaceutical Technology)
03:15AM	Is Mirum Pharmaceuticals About to Soar in 2026? (Motley Fool)
Jan-26-26 08:00AM	Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Jan-22-26 09:52PM	Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results (Insider Monkey)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 05:04AM	3 Top Growth Stocks to Buy in the First Half of 2026 (Motley Fool)
Jan-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Loading…
08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum (Business Wire)
Jan-09-26 11:55AM	Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals (Business Wire) +6.09%
Jan-07-26 04:01PM	Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.22%
Jan-06-26 08:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-04-26 04:05AM	5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right (Motley Fool)
Dec-30-25 03:07AM	Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now (Motley Fool)
Dec-23-25 01:52PM	This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone (Investor's Business Daily)
Dec-19-25 08:30AM	Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX (Business Wire) +10.61%
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 07:44AM	Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition (Insider Monkey)
Dec-09-25 09:45AM	Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald (TipRanks)
09:42AM	Mirum to buy Bluejay for up to $820m in rare liver disease push (Pharmaceutical Technology)
Dec-08-25 08:31AM	Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay (BioPharma Dive)
08:00AM	Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Dec-04-25 11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
06:30AM	Loading…
Dec-03-25 06:30AM	Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 (Motley Fool)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
Dec-01-25 08:10AM	Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-25 08:10AM	Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 04:02PM	Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (Business Wire)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 07:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-10-25 06:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-17-25 12:36PM	Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up (Investor's Business Daily)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
Jun-10-25 08:40PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Data from Mirums VANTAGE PBC Study Showcased at EASL (Business Wire)
May-08-25 12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks) +9.75%
07:08AM	Q1 2025 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:29AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 09:17PM	Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth (Seeking Alpha)
09:17PM	Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-06-25 05:05PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.13%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-04-25 06:45PM	Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities (Seeking Alpha)
Apr-30-25 08:30AM	Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (Business Wire)
Apr-28-25 08:30AM	Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses (Business Wire)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-14-25 08:30AM	Mirums LIVMARLI Now FDA Approved in Tablet Formulation (Business Wire)
Apr-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.67%
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-28-25 11:30AM	Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-25 08:30AM	LIVMARLI Now Approved in Japan for ALGS and PFIC (Business Wire)
Mar-24-25 05:17PM	Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (SeekingAlpha)
12:24PM	Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (SeekingAlpha)
Mar-21-25 12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
Mar-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 10:56AM	Q4 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.02%
02:22AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Feb-26-25 05:15PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (Business Wire)
11:48AM	Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know (Zacks)
Feb-24-25 08:30AM	Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Radovich Peter	PRESIDENT AND COO	Feb 02 '26	Sale	103.30	2,631	271,792	20,655	Feb 03 09:45 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '26	Sale	103.30	9,108	940,888	160,294	Feb 03 09:45 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '26	Sale	103.30	968	99,998	4,503	Feb 03 09:45 PM
Jolanda Howe	Officer	Feb 02 '26	Proposed Sale	103.80	968	100,478		Feb 02 08:29 PM
Peter Radovich	Officer	Feb 02 '26	Proposed Sale	103.80	2,631	273,098		Feb 02 08:25 PM
Christopher Peetz	Officer	Feb 02 '26	Proposed Sale	103.80	9,108	945,410		Feb 02 08:21 PM
Jolanda Howe	Officer	Jan 26 '26	Proposed Sale	96.92	842	81,607		Jan 28 06:47 PM
ERIC BJERKHOLT	Officer	Jan 26 '26	Proposed Sale	96.92	1,053	102,057		Jan 28 06:44 PM
Peter Radovich	Officer	Jan 26 '26	Proposed Sale	96.92	3,143	304,620		Jan 28 06:43 PM
Christopher Peetz	Officer	Jan 26 '26	Proposed Sale	96.92	6,831	662,061		Jan 28 06:40 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	96.19	1,053	101,290	43,741	Jan 27 04:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 26 '26	Sale	96.19	3,143	302,331	23,286	Jan 27 04:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 26 '26	Sale	96.19	842	80,994	3,700	Jan 27 04:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 26 '26	Sale	96.19	6,831	657,088	169,402	Jan 27 04:30 PM
Heron Patrick J	Director	Jan 23 '26	Buy	68.48	131,425	8,999,984	459,010	Jan 27 04:14 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 22 '26	Sale	93.33	926	86,419	3,042	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 22 '26	Sale	93.33	1,822	170,039	12,817	Jan 23 05:30 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 22 '26	Sale	93.33	1,421	132,615	42,127	Jan 23 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 22 '26	Sale	93.33	2,382	222,301	20,679	Jan 23 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 22 '26	Sale	93.33	7,098	662,422	163,733	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 20 '26	Sale	90.27	6,911	623,853	11,305	Jan 21 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Jan 16 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Sale	90.99	2,000	181,980	0	Jan 16 04:05 PM
SAIRA RAMASASTRY	Director	Jan 15 '26	Proposed Sale	90.99	2,000	181,980		Jan 15 04:02 PM
Ramasastry Saira	Director	Dec 22 '25	Option Exercise	23.51	5,000	117,550	5,000	Dec 23 06:52 PM
Ramasastry Saira	Director	Dec 22 '25	Sale	80.00	5,000	400,000	0	Dec 23 06:52 PM
GREY MICHAEL G	Director	Dec 19 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 23 06:50 PM
GREY MICHAEL G	Director	Dec 19 '25	Sale	78.00	50,000	3,900,000	0	Dec 23 06:50 PM
SAIRA RAMASASTRY	Director	Dec 22 '25	Proposed Sale	80.00	5,000	400,000		Dec 22 04:03 PM
Ramasastry Saira	Director	Dec 18 '25	Option Exercise	23.51	2,000	47,020	2,000	Dec 19 04:15 PM
Ramasastry Saira	Director	Dec 18 '25	Sale	69.73	2,000	139,460	0	Dec 19 04:15 PM
MICHAEL GREY	Director	Dec 19 '25	Proposed Sale	78.00	50,000	3,900,000		Dec 19 04:05 PM
SAIRA RAMASASTRY	Director	Dec 18 '25	Proposed Sale	69.73	2,000	139,460		Dec 18 04:09 PM
GREY MICHAEL G	Director	Dec 01 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 02 04:04 PM
GREY MICHAEL G	Director	Dec 01 '25	Sale	74.00	50,000	3,700,000	0	Dec 02 04:04 PM
MICHAEL GREY	Director	Dec 01 '25	Proposed Sale	74.00	50,000	3,700,000		Dec 01 04:07 PM
GREY MICHAEL G	Director	Nov 21 '25	Option Exercise	2.94	50,000	146,800	50,000	Nov 25 04:10 PM
GREY MICHAEL G	Director	Nov 21 '25	Sale	70.00	50,000	3,500,000	0	Nov 25 04:10 PM
MICHAEL GREY	Director	Nov 21 '25	Proposed Sale	70.00	50,000	3,500,000		Nov 21 04:09 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Option Exercise	19.24	19,133	368,119	158,034	Nov 20 04:21 PM
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 12 '25	Option Exercise	26.49	2,954	78,251	31,190	Aug 12 08:00 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 12 07:57 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Sale	62.00	40,000	2,480,000	138,641	Aug 12 07:57 PM
CHRISTOPHER PEETZ	Officer	Aug 11 '25	Proposed Sale	62.00	40,000	2,480,000		Aug 11 04:06 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Option Exercise	6.27	10,000	62,700	12,426	Aug 08 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Sale	58.00	10,000	580,000	2,426	Aug 08 04:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 08 04:49 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Sale	55.25	40,000	2,210,040	138,641	Aug 08 04:49 PM
JOLANDA MARIE HOWE	Officer	Aug 07 '25	Proposed Sale	58.00	10,000	580,000		Aug 07 04:26 PM
CHRISTOPHER PEETZ	Officer	Aug 07 '25	Proposed Sale	55.25	40,000	2,210,040		Aug 07 04:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '25	Sale	48.25	564	27,213	2,903	Jul 03 06:48 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 03 '25	Sale	49.08	477	23,411	2,426	Jul 03 06:48 PM
JOLANDA MARIE HOWE	Officer	Jul 03 '25	Proposed Sale	49.08	477	23,411		Jul 03 01:13 PM
Fairey William	Director	Jun 11 '25	Sale	48.42	3,203	155,091	2,500	Jun 13 04:18 PM
WILLIAM C FAIREY	Director	Jun 11 '25	Proposed Sale	48.42	3,203	155,091		Jun 11 04:05 PM
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 18 '25	Sale	44.45	2,415	107,343	2,426	Mar 19 05:40 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Option Exercise	2.94	52,900	155,526	59,547	Mar 18 09:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Sale	44.35	57,606	2,554,763	4,841	Mar 18 09:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 17 '25	Sale	44.21	7,879	348,364	18,672	Mar 18 09:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Sale	44.21	27,279	1,206,122	138,641	Mar 18 09:30 PM
Heron Patrick J	Director	Mar 14 '25	Buy	44.11	528	23,291	168,651	Mar 18 05:04 PM
Heron Patrick J	Director	Mar 17 '25	Buy	43.93	21	923	168,672	Mar 18 05:04 PM
JOLANDA MARIE HOWE	Officer	Mar 18 '25	Proposed Sale	44.45	2,415	107,343		Mar 18 04:12 PM
JOLANDA MARIE HOWE	Officer	Mar 17 '25	Proposed Sale	44.36	54,706	2,426,540		Mar 17 04:21 PM
Heron Patrick J	Director	Mar 10 '25	Buy	42.97	1,335	57,363	167,160	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 11 '25	Buy	43.77	963	42,155	168,123	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 06 '25	Buy	43.89	1,335	58,597	165,245	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 07 '25	Buy	43.21	580	25,064	165,825	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 04 '25	Buy	45.57	1,335	60,830	163,643	Mar 06 05:30 PM
Heron Patrick J	Director	Mar 05 '25	Buy	44.55	267	11,894	163,910	Mar 06 05:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 04 '25	Sale	45.58	14,850	676,928	12,111	Mar 05 04:28 PM
Radovich Peter	Officer	Mar 04 '25	Proposed Sale	45.52	14,850	675,956		Mar 04 04:43 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	2.94	40,000	117,440	155,920	Mar 04 04:26 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	46.91	40,000	1,876,353	115,920	Mar 04 04:26 PM
CHRISTOPHER PEETZ	Officer	Mar 03 '25	Proposed Sale	46.91	40,000	1,876,280		Mar 03 04:49 PM

DAWN

Day One Biopharmaceuticals Inc

VIR

Vir Biotechnology Inc

MIRM

Mirum Pharmaceuticals Inc

Upgrade your FINVIZ experience